Phathom_Pharm_Logo_RGB.jpg
Phathom Pharmaceuticals Announces Appointment of Molly Henderson as Chief Financial and Business Officer
March 22, 2022 08:02 ET | Phathom Pharmaceuticals
FLORHAM PARK, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Phathom_Pharm_Logo_RGB.jpg
Phathom Pharmaceuticals Submits Vonoprazan NDA to FDA for the Treatment of Erosive Esophagitis
March 14, 2022 08:02 ET | Phathom Pharmaceuticals
FLORHAM PARK, N.J., March 14, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Phathom_Pharm_Logo_RGB.jpg
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Pipeline and Business Progress
March 01, 2022 16:04 ET | Phathom Pharmaceuticals
FLORHAM PARK, N.J., March 01, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Phathom_Pharm_Logo_RGB.jpg
Phathom Pharmaceuticals Announces Positive Topline Results from Phase 2 Trial Evaluating Vonoprazan for Non-Erosive Gastroesophageal Reflux Disease (NERD)
February 09, 2022 16:04 ET | Phathom Pharmaceuticals
Vonoprazan met the primary endpoint for all three dose levels (10 mg, 20 mg, 40 mg) taken on-demand, demonstrating faster and sustained relief of episodic heartburn as compared to placebo...
Phathom_Pharm_Logo_RGB.jpg
Phathom Pharmaceuticals to Participate in the 4th Annual Evercore ISI HealthCONx Conference
November 23, 2021 16:00 ET | Phathom Pharmaceuticals
FLORHAM PARK, N.J., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Phathom_Pharm_Logo_RGB.jpg
Phathom Pharmaceuticals to Participate in Two Upcoming Investor Healthcare Conferences
November 12, 2021 16:30 ET | Phathom Pharmaceuticals
FLORHAM PARK, N.J., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Phathom_Pharm_Logo_RGB.jpg
Phathom Pharmaceuticals Reports Third Quarter 2021 Results and Provides Key Clinical, Regulatory, and Business Updates
November 08, 2021 08:00 ET | Phathom Pharmaceuticals
Two New Drug Applications (NDAs) for vonoprazan-based treatment regimens for H. pylori infection were accepted for filing by FDA with six-month Priority Review granted; PDUFA target action date of May...
Phathom_Pharm_Logo_RGB.jpg
Phathom Pharmaceuticals Withdraws Public Offering
October 27, 2021 21:47 ET | Phathom Pharmaceuticals
FLORHAM PARK, N.J., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Phathom_Pharm_Logo_RGB.jpg
Phathom Pharmaceuticals Announces Proposed Public Offering of 5,000,000 Shares of Common Stock
October 26, 2021 16:01 ET | Phathom Pharmaceuticals
FLORHAM PARK, N.J., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Phathom_Pharm_Logo_RGB.jpg
Phathom Pharmaceuticals Announces New Data at ACG 2021 Annual Scientific Meeting
October 24, 2021 15:30 ET | Phathom Pharmaceuticals
Data from Phase 3 PHALCON-HP trial highlighted in oral presentation and recognized with the ACG Governors Award for Excellence in Clinical ResearchPhase 1 population PK data abstract concludes the...